Life Molecular Imaging (LMI) has inked strategic partnership and licensing agreement with PharmaLogic to provide and distribute Neuraceq from PharmaLogic's radiopharmaceutical manufacturing site located near Denver, CO. 

Neuraceq is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

Neuraceq is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases.

"By partnering with PharmaLogic and offering Neuraceq in Denver, Life Molecular Imaging is excited to expand access of Neuraceq for the detection of beta-amyloid plaques in the brain. We believe this additional access benefits physicians and patients, as well as our pharma partners for routine clinical and research use. We are excited to collaborate with Pharmalogic today and look forward to more opportunities in the future. " said Ludger Dinkelborg, PhD, Managing Director at LMI.

"Expanding patient access to clinically-impactful radiopharmaceuticals is a core component of our mission," said Steve Chilinski, CEO of PharmaLogic.

"By partnering with Life Molecular Imaging in Denver, patients in the greater Rocky Mountain region will have even greater access to a new wave of disease targeting diagnostic radiopharmaceuticals," Chilinski added.